In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on BioPharmX Corp (BPMX – Research Report), with a price target of $1. The company’s shares closed yesterday at $0.16.
“Yesterday, after the Market close, BPMX reported a F3Q19 (Sep) GAAP loss per share inline with both our estimate and consensus.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 6.4% and a 48.9% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.
The the analyst consensus on BioPharmX Corp is currently a Hold rating.
Based on BioPharmX Corp’s latest earnings release for the quarter ending July 31, the company reported a quarterly GAAP net loss of $4.41 million. In comparison, last year the company had a GAAP net loss of $3.71 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioPharmX Corp. engages in the provision of healthcare products through platform technologies for pharmaceutical, over-the-counter, and supplement applications in dermatology. Its platforms include Topical Gel, Injectable, and Encapsulation.